Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06076499 · ClinicalTrials.gov registry record
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
A clinical trial of Restless Legs Syndrome, sponsored by Noctrix Health.
- Active
- Registry status
- 325
- Enrollment target
- 6
- Study locations
NCT06076499: Active study of Restless Legs Syndrome, sponsored by Noctrix Health.
NCT06076499 is a study of Restless Legs Syndrome that is active but no longer recruiting, run by Noctrix Health. The registered enrollment target is 325 participants, above the 73-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (345% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06076499, a study of Restless Legs Syndrome, is active but no longer recruiting, sponsored by Noctrix Health.
- ACTIVE NOT RECRUITING
- Registry status
- 325 participants
- Enrollment target
- 6
- Study locations
Study Summary
Multi-center post-market, observational study to assess the long-term effectiveness and safety of the NTX100 TOMAC System for patients with Restless Legs Syndrome.
Primary Outcome
Change from baseline (study entry) in IRLS total score at 1-year.
Conditions Studied
Interventions
- DEVICE NTX100
Study Locations (6)
California
- Mark J Buchfuhrer, MD Office - Downey
- Sleep Medicine Specialists of California - San Ramon
Massachusetts
- Neurocare, Inc. - Newton
Missouri
- Clayton Sleep Institute - St Louis
Ohio
- Ohio Sleep Medicine and Institute - Dublin
South Carolina
- Bogan Sleep Consultants, LLC - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2026-12 |
What the registry record for NCT06076499 still lists
NCT06076499 is an observational study that tracks outcomes without assigning an intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, above the 73-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (345% higher).
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which NTX100 is the first listed.
NCT06076499 lists 6 locations in 5 states (California, Massachusetts, Missouri).
Frequently Asked Questions
What is clinical trial NCT06076499 about?
NCT06076499 is a clinical study titled "A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS". Multi-center post-market, observational study to assess the long-term effectiveness and safety of the NTX100 TOMAC System for patients with Restless Legs Syndrome.
What is the current status of trial NCT06076499?
This trial is currently active not recruiting. The enrollment target is 325 participants. The study started on 2023-11-15. Estimated completion is 2026-12.
What conditions does trial NCT06076499 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT06076499?
The interventions under investigation include: NTX100 (DEVICE).
Who is sponsoring clinical trial NCT06076499?
This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06076499 being conducted?
This trial has 6 study locations across California, Massachusetts, Missouri, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06076499's enrollment target sits among peer trials
325 2nd of 14 the highest of 14 other Restless Legs Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Restless Legs Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
COMPLETED · Phase 1
-
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI